Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction

Clinical Trial of Bile Etiology,Proteomics and Metabonomics of Malignant Biliary Obstruction

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01073514

Acronym

MBO-IR

Enrollment

300

Registered

2010-02-23

Start date

2009-12-31

Completion date

2016-12-31

Last updated

2015-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Biliary Obstruction

Keywords

Malignant biliary obstruction (MBO)

Brief summary

To investigate bile culture and susceptibility test in patients with malignant biliary obstruction (MBO) or relation between bile, portal vein or vein culture and biliary infection. Also to get the information of bile metabonomics to find potential tumor marker .Culture of the organism is recognized as the gold standard for diagnosis of infection. Our research may be one of the first research on culture and susceptibility test in patients with MBO. The results of the trial research will be benefit to experiential therapy of MBO with biliary infection and diagnosis of MBO.

Detailed description

We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after PTBD. Also get the blood and urine samples.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion criteria

* Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Countries

China

Contacts

Primary ContactYU HAI PENG, MD

JIERUKE@YAHOO.COM.CN13352070835

Outcome results